Browsing by Author "Le, Yi"

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
    Brainstem metastases treated with Gamma Knife stereotactic radiosurgery: the Indiana University Health experience
    (Future Medicine:, 2018-01) Patel, Ajay; Mohammadi, Homan; Dong, Tuo; Shiue, Kevin Ren-Yeh; Frye, Douglas; Le, Yi; Ansari, Shaheryar; Watson, Gordon A.; Miller, James C.; Lautenschlaeger, Tim; Medicine, School of Medicine
    Brainstem metastases offer a unique challenge in cancer treatment, yet stereotactic radiosurgery (SRS) has proven to be an effective modality in treating these tumors. This report discusses the clinical outcomes of patients with brainstem metastases treated at Indiana University with Gamma Knife (GK) radiosurgery from 2008 to 2016. 19 brainstem metastases from 14 patients who had follow-up brain imaging were identified. Median tumor volume was 0.04 cc (range: 0.01-2.0 cc). Median prescribed dose was 17.5 Gy to the 50% isodose line (range: 14-22 Gy). Median survival after GK SRS treatment to brainstem lesion was 17.2 months (range: 2.8-45.6 months). The experience at Indiana University confirms the safety and efficacy of range of GK SRS prescription doses (14-22 Gy) to brainstem metastases.
  • Thumbnail Image
    Item
    CT and MRI fusion for postimplant prostate brachytherapy evaluation
    (IEEE, 2016-04) Dehghan, Ehsan; Le, Yi; Lee, Junghoon; Song, Danny; Prince, Jerry L.; Fichtinger, Gabor; Department of Radiation Oncology, IU School of Medicine
    Postoperative evaluation of prostate brachytherapy is typically performed using CT, which does not have sufficient soft tissue contrast for accurate anatomy delineation. MR-CT fusion enables more accurate localization of both anatomy and implanted radioactive seeds, and hence, improves the accuracy of postoperative dosimetry. We propose a method for automatic registration of MR and CT images without a need for manual initialization. Our registration method employs a point-to-volume registration scheme during which localized seeds in the CT images, produced by commercial treatment planning systems as part of the standard of care, are rigidly registered to preprocessed MRI images. We tested our algorithm on ten patient data sets and achieved an overall registration error of 1.6 ± 0.8 mm with a running time of less than 20s. With high registration accuracy and computational speed, and no need for manual intervention, our method has the potential to be employed in clinical applications.
  • Thumbnail Image
    Item
    Deformable registration of X-ray and MRI for post-implant dosimetry in low-dose-rate prostate brachytherapy
    (Wiley, 2019) Hrinivich, William T.; Park, Seyoun; Le, Yi; Song, Daniel Y.; Lee, Junghoon; Radiation Oncology, School of Medicine
    Purpose Dosimetric assessment following permanent prostate brachytherapy (PPB) commonly involves seed localization using CT and prostate delineation using coregistered MRI. However, pelvic CT leads to additional imaging dose and requires significant resources to acquire and process both CT and MRI. In this study, we propose an automatic postimplant dosimetry approach that retains MRI for soft‐tissue contouring, but eliminates the need for CT and reduces imaging dose while overcoming the inconsistent appearance of seeds on MRI with three projection x rays acquired using a mobile C‐arm. Methods Implanted seeds are reconstructed using x rays by solving a combinatorial optimization problem and deformably registered to MRI. Candidate seeds are located in MR images using local hypointensity identification. X ray‐based seeds are registered to these candidate seeds in three steps: (a) rigid registration using a stochastic evolutionary optimizer, (b) affine registration using an iterative closest point optimizer, and (c) deformable registration using a local feature point search and nonrigid coherent point drift. The algorithm was evaluated using 20 PPB patients with x rays acquired immediately postimplant and T2‐weighted MR images acquired the next day at 1.5 T with mean 0.8 × 0.8 × 3.0 mmurn:x-wiley:00942405:media:mp13667:mp13667-math-0001 voxel dimensions. Target registration error (TRE) was computed based on the distance from algorithm results to manually identified seed locations using coregistered CT acquired the same day as the MRI. Dosimetric accuracy was determined by comparing prostate D90 determined using the algorithm and the ground truth CT‐based seed locations. Results The mean ± standard deviation TREs across 20 patients including 1774 seeds were 2.23 ± 0.52 mm (rigid), 1.99 ± 0.49 mm (rigid + affine), and 1.76 ± 0.43 mm (rigid + affine + deformable). The corresponding mean ± standard deviation D90 errors were 5.8 ± 4.8%, 3.4 ± 3.4%, and 2.3 ± 1.9%, respectively. The mean computation time of the registration algorithm was 6.1 s. Conclusion The registration algorithm accuracy and computation time are sufficient for clinical PPB postimplant dosimetry.
  • Thumbnail Image
    Item
    Dosimetric Impact of Source Displacement in GammaTile Surgically Targeted Radiation Therapy for Gliomas
    (Springer Nature, 2023-05-02) Ng, Sook Kien; Yue, Yong; Shiue, Kevin; Shah, Mitesh V.; Le, Yi; Radiation Oncology, School of Medicine
    Background: This study aims to evaluate dosimetric changes that happened during the first month after GammaTile surgically targeted radiation therapy (STaRT) for gliomas due to Cesium-131 (Cs-131) seed displacement caused by cavity shrinkage in brain brachytherapy. Methodology: In this study, 10 glioma patients had 4-11 GammaTiles placed along the resection bed after maximal safe resection during craniotomy. Each GammaTile is composed of four Cs-131 seeds embedded in a biodegradable collagen sponge to minimize seed movement and maintain seed-to-cavity surface distance. The Cs-131 seed positions were identified using VariSeed on day one. On day 30, post-implant computed tomography (CT) images and dosimetry parameters were calculated. An iterative closest point (ICP) algorithm was used to compute rigid transformation between the day one and day 30 seed clouds. The seed displacement was calculated after registration. The volume receiving 100% of the prescription dose (V100), the dose received by 90% of the planning target volume (D90_PTV), the planning target volume receiving 100% of the prescription dose (V100_PTV), and the dose to organs at risk (OARs) were calculated for both CT images to determine the dosimetric changes from any seed displacement. Results: The mean seed displacement of 1.8 ± 1.0 mm for all patients was observed between day one and day 30. The maximum seed displacement for each patient ranged from 2.3 mm to 7.3 mm. The mean V100 difference between day one and day 30 was 2.5 cc (range = 0.5-6.5 cc). The mean D90_PTVs were 95.5% (range = 69.0%-131.0%) and 98.1% (range = 19.9%-149.0%) on day one and day 30, respectively. The mean V100_PTVs were 88.4% (range = 81.3%-99.1%) and 87.9% (range = 47.0%-99.7%) on day one and day 30, respectively. On day one, the brainstem dose was 63.5 Gy for one case and 28.1 Gy for another case; while on day 30, the brainstem dose was 55.8 Gy and 20.6 Gy for the same patients, contributing to 7.7 Gy (12.8%) and 7.5 Gy (12.5%) dose reductions to brainstem for these patients, respectively. Only two patients received a dose to the optic nerves (34.1 Gy and 5.2 Gy). There were small changes (1.8 Gy and 0.5 Gy, respectively) in the dose to optic nerves when comparing the dose calculated on day one and the dose calculated on day 30 CT images. The same two patients received 30.4 Gy and 6.8 Gy to the chiasm, respectively. Small changes in the dose to the chiasm (≤1.1 Gy) were noted between day one and day 30. Conclusions: A maximum seed displacement of up to 7.3 mm and a mean seed displacement of 1.8 mm caused by cavity shrinkage were observed during the first month after GammaTile STaRT for gliomas. There were noticeable changes in dosimetry parameters. Changes in the doses to OARs, particularly the brainstem, were large (up to 12.8% of the prescription dose). These changes in dosimetry should be considered when evaluating treatment outcomes and planning future GammaTile treatments.
  • Thumbnail Image
    Item
    GammaTile for Gliomas: A Single-Center Case Series
    (Springer Nature, 2021-11) Budnick, Hailey C.; Richardson, Angela M.; Shiue, Kevin; Watson, Gordon; Ng, Sook K.; Le, Yi; Shah, Mitesh V.; Radiation Oncology, School of Medicine
    GammaTile® (GT Medical Technologies, Tempe, Arizona) is a surgically targeted radiation source, approved by FDA for brachytherapy in primary and secondary brain neoplasms. Each GammaTile is composed of a collagen sponge with four seeds of cesium 131 and is particularly useful in recurrent tumors. We report our early experience in seven patients with recurrent gliomas to assess this type of brachytherapy with particular attention to ease of use, complication, and surgical planning. This study represents a retrospective chart review of surgical use and early clinical outcomes of GammaTile in recurrent gliomas. The number of tiles was planned using pre-operative imaging and dosimetry was planned based on post-operative imaging. Patients were followed during their hospital stay and were followed up after discharge. Parameters such as case length, resection extent, complication, ICU length of stay (LOS), hospital LOS, pre-operative Glasgow Coma Scale (GCS), immediate post-operative GCS, post-operative imaging findings, recurrence at follow-up, length of follow-up, and dosimetry were collected in a retrospective manner. Seven patients were identified that met the inclusion criteria. Two patients were diagnosed with recurrent glioblastoma multiforme (GBM), one lower-grade glioma that recurred as a GBM, one GBM that recurred as a gliosarcoma, and two recurrent oligodendrogliomas. We found that operation time, ICU LOS, hospital LOS, pre- and post-operative GCS, and post-operative complications were within the expected ranges for tumor resection patients. Further, dosimetry data suggests that six out of seven patients received adequate radiation coverage, with the seventh having implantation limitations due to nearby organs at risk. We report no postoperative complications that can be attributed to the GammaTiles themselves. In our cohort, we report seven cases where GammaTiles were implanted in recurrent gliomas. No implant-related post-operative complications were identified. This early data suggests that GammaTile can be a safe form of brachytherapy in recurrent gliomas.